CD4 and allergic disease: An alternative to SIT is the use of peptides containing CD4+ T‐cell epitopes derived from clinically important allergens.3 Peptide immunotherapy performed with short peptides is associated with fewer IgE‐mediated adverse events than observed in conventional SIT, since short peptides have a markedly reduced ability to cross‐link IgE on basophils (and by inference mast cells).5 Peptide immunotherapy has been shown to effectively ameliorate symptoms of allergic disease in both mice and humans.2, 5, 6, 7, 8, 9